Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20–25% of patients are prescribed a higher dose than the maximum recommended dosage of nine breaths per treatment session (bps) (54 μg), four times a day (QI...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2021-10-01
|
| Colección: | Pulmonary Circulation |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1177/20458940211052228 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|